Neurocrine Biosciencesvs.Vertex Pharmaceuticals
NBIX vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 8.7× larger than Neurocrine Biosciences by market cap; Neurocrine Biosciences trades at the lower P/E (22.0 vs 30.7); year to date, Vertex Pharmaceuticals leads (+20.8% vs +7.9%).
Side by side
| NBIX | VRTX | |
|---|---|---|
| Market cap | $15.5B | $135B |
| Price | $153.37 | $552.85 |
| Today | +0.2% | +1.0% |
| Return YTD | +7.9% | +20.8% |
| Return 1Y | +13.0% | +38.6% |
| P/E | 22.0 | 30.7 |
| P/S | 4.6 | 10.7 |
| P/B | 4.2 | 6.7 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Neurocrine BiosciencesNBIX
Ingrezza for tardive dyskinesia, plus a wider neurology and endocrine portfolio.
Full NBIX profile →Vertex PharmaceuticalsVRTX
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Full VRTX profile →More NBIX & VRTX comparisons
Other head-to-heads in the Biotech & innovation segment.
See where NBIX and VRTX sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →